BioStem Technologies, Inc. Common Stock vs. Moderna, Inc. Common Stock
BSEM
BioStem Technologies, Inc. Common Stock
$3.87 +5.74%
VS MRNAModerna, Inc. Common Stock
$142.77 -4.60%
BioStem Technologies, Inc. Common Stock and Moderna, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| BSEM | MRNA | |
|---|---|---|
| Market Cap | $65.26 million | $59.75 billion |
| Revenue (TTM) | — | $2.23 billion |
| Net Income (TTM) | — | $-3,151,000,000 |
MRNA leads on 1 of 1 size & scale factors.
Valuation
| BSEM | MRNA | |
|---|---|---|
| Price / Book | — | 8.84 |
| Price / Sales | — | 26.82 |
BSEM and MRNA split the valuation factors evenly.
Profitability
| BSEM | MRNA | |
|---|---|---|
| Net Margin | — | -141.43% |
| Return on Equity | — | -46.61% |
BSEM and MRNA split the profitability factors evenly.
Risk & Sentiment
| BSEM | MRNA | |
|---|---|---|
| Short Interest | 0.00% | 0.01% |
BSEM leads on 1 of 1 risk & sentiment factors.
Dig deeper: BSEM overview, BSEM financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.